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Background: In this study we determined if treatment combining radiation therapy (RT) with intracerebral (i.c.)
administration of carboplatin to F98 glioma bearing rats could improve survival over that previously reported by
us with a 15 Gy dose (5 Gy × 3) of 6 MV photons.
Methods: First, in order to reduce tumor interstitial pressure, a biodistribution study was carried out to determine
if pretreatment with dexamethasone alone or in combination with mannitol and furosemide (DMF) would increase
carboplatin uptake following convection enhanced delivery (CED). Next, therapy studies were carried out in rats that
had received carboplatin either by CED over 30 min (20 μg) or by Alzet pumps over 7 d (84 μg), followed by RT
using a LINAC to deliver either 20 Gy (5 Gy × 4) or 15 Gy (7.5 Gy × 2) dose at 6 or 24 hrs after drug administration.
Finally, a study was carried out to determine if efficacy could be improved by decreasing the time interval between
drug administration and RT.
Results: Tumor carboplatin values for D and DMF-treated rats were 9.4 ±4.4 and 12.4 ±3.2 μg/g, respectively, which
were not significantly different (P = 0.14). The best survival data were obtained by combining pump delivery with 5
Gy × 4 of X-irradiation with a mean survival time (MST) of 107.7 d and a 43% cure rate vs. 83.6 d with CED vs. 30-35
d for RT alone and 24.6 d for untreated controls. Treatment-related mortality was observed when RT was initiated
6 h after CED of carboplatin and RT was started 7 d after tumor implantation. Dividing carboplatin into two 10 μg
doses and RT into two 7.5 Gy fractions, administered 24 hrs later, yielded survival data (MST 82.1 d with a 25%
cure rate) equivalent to that previously reported with 5 Gy × 3 and 20 μg of carboplatin.
Conclusions: Although the best survival data were obtained by pump delivery, CED was highly effective in
combination with 20 Gy, or as previously reported, 15 Gy, and the latter would be preferable since it would
produce less late tissue effects.
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Although cisplatin and carboplatin are highly effective
anti-cancer drugs, which have been used clinically to
treat a variety of malignancies, they have not been effect-
ive in patients with high grade gliomas [1]. Despite the
fact that their tumoricidal activity can be demonstrated
in vitro [2], their systemic toxicity, high water solubility,* Correspondence: rolf.barth@osumc.edu
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reproduction in any medium, provided the orand inability to effectively penetrate the blood-brain
barrier (BBB) have limited their usefulness for treating
patients with brain tumors. A European Organization
for Research and Treatment of Cancer (EORTC) clinical
trial in patients with supratentorial malignant gliomas,
who had received a combination of cisplatin and RT,
failed to demonstrate any improvement in either progres-
sion free or overall survival [3]. This brought to an end
any further clinical studies to investigate the combination
of platinum (Pt) compounds and photon radiation to treat
high grade gliomas.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by Elleaume and her research team in France [4-8] and
by us in the United States [9] to evaluate intracere-
bral (i.c.) delivery of either cisplatin or carboplatin in
combination with RT. This combination has produced
the best survival data that ever have been reported
with the F98 rat glioma model [10]. The purpose of
the present study was to determine if therapeutic effi-
cacy could be improved over that previously reported
by [9] using two different RT regimens in combin-
ation with i.c. administration of carboplatin by either
convection enhanced delivery (CED) or Alzet pump
delivery. Both of these approaches can deliver a thera-
peutic agent directly to the site of the brain tumor,
completely bypassing the BBB and allowing one to
obtain a drug concentration that can be up to 1,000×
greater than that achieved by systemic administration
of carboplatin [9]. In the present study the best sur-
vival data and cure rates were obtained by administer-
ing carboplatin via Alzet osmotic pumps or CED in
combination with a 5 Gy × 4 fractionated dose of 6
MV photons with no treatment-related mortality. How-
ever, equivalent survival data were reported previously by
us [9] using a fractionated 15 Gy dose (5 Gy × 3), and the
latter appears to be the optimum regimen since it would
reduce long term radiation related effects on the brain.
Methods
F98 rat glioma model
The F98 rat glioma has been propagated in vitro and
in vivo since 1971 and, as described in a recent review
[10], it has been used in a wide variety of studies in
experimental neuro-oncology. It is a radioresistant tumor
that is invariably fatal with an inoculum of as few as 100
cells. F98 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 5% fetal bovine serum, as
previously described [9]. All animal studies were carried
out in accordance with the Guide for the Care and Use of
Laboratory Animals (National Academy Press, Washington,
DC, 1996) and the protocol was approved by the Institu-
tional Laboratory Animal Care and Use Committee. Male
Fischer rats (Animal Production Branch, National Cancer
Institute, Frederick, MD) weighing ~200–220g were used
in the present study. A stereotactic implantation proced-
ure was employed [11]. F98 glioma cells were suspended
in DMEM containing low gelling temperature agarose at a
concentration of either 103 cells/10 μl for therapy studies
or 105 cells/10 μl for biodistribution studies. These were
injected into the right caudate nucleus over 10-15 sec.
Biodistribution of carboplatin in F98 glioma bearing rats
A greater number of cells were used for biodistribution
studies in order to have a larger tumor mass for
determination of carboplatin concentrations. In order toreduce tumor interstitial pressure [12], a biodistribution
study was carried out to determine if pretreatment with
dexamethasone (D), alone or in combination with man-
nitol and furosemide (DMF) would increase the tumor
uptake of carboplatin in F98 glioma bearing rats follow-
ing i.c. convection enhanced delivery (CED) compared
to untreated rats. Eleven to 13 d after tumor implantation,
biodistribution studies were initiated in either untreated
rats or those that had received either intraperitoneal (i.p.)
D (3 mg/kg b.w.) daily × 3 alone or in combination with
intravenous (i.v.) M (2.5 g/kg b.w.) at 0.25 ml/min over 10
min and i.v. F (2 mg/kg b.w.) over 15 min. As reported by
Boucher et al., this regimen produced a marked reduction
in the intratumoral interstitial fluid pressure in F98 glioma
bearing rats [12]. Carboplatin (Hospira Inc. Lake Forrest,
IL) was administered by CED (0.33 μl/min over 30 min)
[9]. Immediately following termination of CED, samples of
blood were taken and the animals were euthanized, their
brains were removed, tumors were carefully dissected out,
weighed, frozen, and stored at −20°C and eventually
processed for Pt determinations by means of inductively
coupled plasma–optical emission spectroscopy (ICP-OES)
[9]. Based on the atomic weight of Pt (195.1), the concen-
trations of carboplatin (M.W. 371 Da) were calculated by
multiplying the Pt values by 1.90.
Therapy studies
The first set of experiments was carried out using a
20 μg dose of carboplatin, administered i.c. by CED
(0.33 μl/min) over 30 min at either 7 d or 13 d after
tumor cell implantation or alternatively by infusion
using Alzet osmotic pumps (model #2001, Durect Corp.,
Cupertino, CA) over 7 d (84 μg in 168 μl at 1 μl/hr). In
order to determine if the time interval between drug
administration and RT would improve survival times, rats
were irradiated at either 6 or 24 hr later with 6 MV
photons using a Siemens Mevatron linear accelerator.
The rats were irradiated under continuous isoflurane
anesthesia in a specially fabricated circular plexiglas
chamber divided into 4 compartments radiating out from
the center. The animals’ bodies were shielded using a
pinwheel-shaped cerrobend block so that only the right
cerebral hemisphere of their heads, which were pointed
inwards towards the center, was irradiated. The chamber
had an inlet and outlet for administration of isoflurane
and oxygen via an anesthesia machine (model Aestiva/5
7900, GE Datex-Ohmeda). The tumor bearing right cere-
bral hemisphere was irradiated in either four 5 Gy or two
7.5 Gy fractions. The radiation dose was calculated to
mid-point of the brain along the anterior-posterior axis. In
the second study, rats received two divided doses of
carboplatin (10 μg in 20 μl) by CED on days 13 and 15
following tumor implantation and they were irradiated
with 7.5 Gy on days 14 and 16.
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All experimental animals were weighed 3 times per week
and their clinical status was evaluated at the same time.
Once the animals had progressively growing tumors, as
evidenced by sustained weight loss (20% of their body
weight following treatment) they were euthanized by
exposure to CO2. Survival times were determined by
adding 1-2 days to the time between tumor implant-
ation and euthanization. Rats surviving > 180 d were
designated as “cured” and were euthanized. The brains of
all animals in the therapy studies were removed after
death, and processed for neuropathologic examination,
stained with hematoxylin and eosin (H&E), and examined
microscopically.Neuropathologic evaluation of glioma bearing rats
following CED of carboplatin and X-irradiation
Four groups, consisting of 6–7 tumor bearing rats each,
received CED of carboplatin (20 μg in 10 μl) on d 13 or
14 following implantation of 104 F98 glioma cells and
were irradiated with four 5 Gy fractions beginning 24 hr
following CED. Cohorts of 6–7 rats were euthanized at
1, 2, 3, or 4 weeks following termination of X-irradiation
(25, 32, 39, and 46 d following implantation). Their
brains were removed, fixed in 10% buffered formalin,
sectioned coronally, and then processed for neuropatho-
logic examination.Statistical evaluation of data
The mean carboplatin concentrations ± standard devia-
tions were computed for tumor and the right and left
cerebral hemispheres for both untreated and DMF-
treated animals. A two-tailed, two sample t test was used
to determine statistical significance (P-value ≤0.05). To
study the effects of treatment on survival, the MST,
standard error (SE), and median survival time (MeST)
were calculated for each group and Kaplan-Meier
survival curves were plotted. An overall Log Rank test
was performed to test for equality of survival curves over
the six groups, and between individual groups [13]. The
overall α level was 0.05, and multiple comparisons were
adjusted using the Bonferroni correction [14]. The per-
cent increased life span was determined, as previously
described [15]. In order to determine the sample size
that would have been required to demonstrate statistical
significance following CED of carboplatin to untreated
and DMF-treated rats, sample size calculations were car-
ried out using SAS 9.3 (SAS Institute, Cary, NC). Proc
Power procedure with a one-way ANOVA. Sample sizes
were calculated with power = 0.8, based on the group
means and pooled standard deviation of the Pt con-
centration in tumor of untreated rats vs DMF-treated
rats with an α level = 0.05.Results
Biodistribution studies
The biodistribution data for two groups of eight F98 gli-
oma bearing rats that had received 20 μg of carboplatin
either alone or following pre-treatment with either D
alone or DMF are summarized in Table 1. Since the
carboplatin values following the administration of dexa-
methasone D alone or DMF were equivalent, these values
were combined. The mean tumor values and ranges for rats
that received carboplatin alone were 9.41 ±4.40 μg/g and
3.02–17.10 μg/g, respectively. The corresponding values for
rats pre-treated with DMF were 12.43 ±3.17 μg/g and
8.55–18.51 μg/g. Although these differences in carbo-
platin values were not significant (P = 0.14) there was a
suggestion that DMF treatment increased the tumor
carboplatin concentrations. In contrast to the broad
ranges that were seen in the tumor carboplatin values,
the normal brain values for the right (tumor bearing)
and left cerebral hemispheres were all in a very narrow
range. The carboplatin values in normal brain of un-
treated vs. DMF treated rats were not significantly dif-
ferent (P = 0.22 and 0.52 for right and left cerebral
hemispheres, respectively).
Therapeutic efficacy of X-irradiation in combination with
i.c. carboplatin
In the first series of experiments, a radiation dose of
20 Gy in four 5 Gy fractions was administered to the
right, tumor bearing cerebral hemisphere in combin-
ation with 20 μg of carboplatin, administered by CED
or 84 μg by Alzet pump infusion. The survival data
are summarized in Table 2 and Kaplan-Meier survival
plots are shown in Figure 1. The best survival data
with no treatment-related toxicity were seen in rats
that received carboplatin via Alzet pumps between
days 7 and 13 following tumor implantation with a MST of
107.7 ±20.7 d and a cure rate (i.e., survival > 180 d) of 43%.
Rats that received carboplatin by CED on day 13, followed
24 hrs later by the initiation of RT, had a MST of 83.6 ±
21.5 d, with a 25% cure rate. If RT was initiated 6 hrs
following CED, the MST was 80.6 ± 18.5 d. However, there
were 2 of 8 treatment-related early deaths (d 27and 29)
and if these were excluded, the cure rate was 29%. If
administration of carboplatin by CED was carried out on d
7 following implantation and RT was initiated on d 8, the
MST was 72.1 ± 17.3 d and a cure rate of 25% with 2 or 8
early treatment-related deaths (d 9 and 10), which were
attributed to cerebral edema. In contrast, untreated con-
trols had a MST of 24.6 ± 1.1 d and X-irradiated rats had
an MST of 35.3 ± 1.8d, both within a very narrow range
compared to rats that received RT in combination with
carboplatin, which had very broad ranges. Using the Log
Rank test, the overall difference between the various treat-
ment groups and untreated controls was highly significant
Table 1 Biodistribution of carboplatin in F98 glioma bearing rats following CED in either untreated or dexamethasone,
mannitol, and furosemide treated ratsa
Carboplatin concentration (μg/g tissue)b
Animal no. Untreated DMF treated
Tumor R Brain L Brain Tumor R Brain L Brain
1 3.02 1.41 1.35 8.55 1.63 1.01
2 6.34 0.82 0.45 10.16 1.22 0.78
3 7.92 1.55 1.00 10.63 1.83 1.12
4 8.15 1.13 0.92 10.64 1.79 0.83
5 8.84 1.62 0.88 12.85 3.10 1.34
6 9.84 0.92 0.30 13.32 0.95 0.99
7 14.10 2.05 0.84 14.81 1.30 0.82
8 17.10 1.74 1.34 18.51 2.28 0.96
Mean ± SDc 9.41 ±4.40 1.41 ±0.42 0.89 ±0.37 12.43 ±3.17 1.76 ±0.68 0.98 ±0.18
Median 8.50 1.48 0.90 11.75 1.71 0.98
Tumor: brain ratios 6.7:1 10.6:1 7.1:1 12.7:1
aRats received either i.p. dexamethasone (D) (3 mg/kg b.v. daily for 3 days) or i.p. dexamethasone (D) followed by i.v. mannitol (M) (2.5 g/kg b.w.) at 0.25 ml/min
over 10 min, followed 15 min later by i.v. furosemide (F) (2 mg/kg b.w.). Since the carboplatin values were equivalent, these were combined.
bRats were euthanized at ~20 min following termination of CED, their brains removed, tumors dissected out, as well as the remainder of the tumor bearing right
and non-tumor bearing left cerebral hemispheres. Platinum concentrations were determined by means of ICP-OES and then converted to carboplatin by
multiplying by 1.9.
cSD designates the standard deviation.
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were X-irradiated vs. those that received combination
therapy (P ≤0.003).
In the second series of experiments, a 15 Gy dose
(7.5 Gy × 2 fraction) in combination with carboplatin
(10 μg/d × 2 d) was carried out to determine if the
survival data could be improved if the carboplatin
dose was divided so that a higher drug concentration
would be available at the time that RT was initiated.
These data are summarized in Table 3 and Figure 1.
The MST of these rats was 82.1 ±15.5 d with a 25%
cure rate and no treatment-related early deaths. Rats
that received a divided dose of carboplatin alone byTable 2 Survival data of F98 rats following CED of carboplatin
Treatment groupa N Mean
Untreated controls 5 24.6
X-irradiation 5 35.3
CED of carboplatin (on day 13) + X-irradiation (6 h later) 8c 80.6 ±
CED of carboplatin (on day 13) + X-irradiation 8 83.6
CED of carboplatin (on day 7) + X-irradiation 8d 72.1 ±
Alzet pump deliverye (d 7-13) + X-irradiation 8 107.7
aStereotactic intracerebral implantation of 103 F98 glioma cells was carried out on d
delivery at a flow rate of 0.33 μL/min. for 30 min. on d 13 following implantation. A
(168 μl at 1 μl/h). Animals received 20 Gy of 6 MV LINAC X-rays, delivered in 5 Gy f
bN indicates the number of animals per group and SE designates the standard erro
tumors. The number in parenthesis indicates the number of long-term survivors.
cThree treatment-related early deaths on d 27 and 29 were included in these calcul
dTwo treatment-related early deaths on d 9 and 10 were included in these calculati
eCarboplatin was administered by Alzet pump (84 μg over 168 hr) followed 24 hr laCED had a MST of 46.8 ±7.5 d, and those that only had
received RT had a MST of 30.0 ±1.9 d (P = 0.0006).
Neuropathologic examination of the brains of the non-
surviving rats that received carboplatin by either CED or
Alzet pump delivery, followed by X-irradiation, revealed
both macroscopic and microscopic deposits of tumor at
the times of their deaths. In contrast, the brains of the
long-term survivors (>180 d) showed no microscopic
evidence of tumor.
A summary of the radiation dosing schedules and the
equivalent doses compared to conventional 2 Gy frac-
tions are shown in Table 4. Based on these calculations,
a 15 Gy dose in three 5 Gy fractions, as previouslyin combination with X-irradiation
Survival times (days)b % Increased life span
± SE Median Range Mean Median
±1.1 25 21–28 0 0
±1.8 35.5 31–39 43 42
18.5c 48 27- > 180(2) 227 92
±21.5 55.5 39- > 180(2) 240 122
17.3d 49 9- > 180(2) 193 96
±21 62 42- > 180(3) 337 148
0. Carboplatin (20 μg in 10 μL) was administered by convectionenhanced
lternatively, they received 84 μg of the drug by Alzet pumps over 7 d
ractions beginning 24 hrs after CED unless otherwise indicated.
r. Survival of >180 d indicates that these animals have been cured of their
ations.
ons.
ter by X-irradiation.
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Figure 1 Kaplan-Meier survival plots of F98 glioma bearing rats following administration of carboplatin by CED or Alzet pumps in
combination with X-irradiation. Survival times in days after implantation have been plotted for untreated animals (●), X-irradiation only
(5 Gy × 4) (○), CED of carboplatin (20 μg) + X-irradiation 6 h later (▼), CED of carboplatin (20 μg) at 7 d + X-irradiation (Δ), CED of carboplatin
(20 μg) + X-irradiation 24 h later (■), carboplatin (84 μg) administered by Alzet pumps + X-irradiation (□), and CED of carboplatin (10 μg × 2) on
days 13 and 15 + X-irradiation (7.5 Gy × 2) on days 14 and 16 (♦).
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sparing and produced identical MSTs in F98 glioma
bearing rats compared to 20 Gy in four 5 Gy fractions
(83.4 d vs. 83.6 d, respectively).
Neuropathologic evaluation following combination
therapy
At one week following administration of carboplatin (20 μg)
by CED and termination of X-irradiation (5 Gy × 4), the
brains of only 2 of 7 rats were microscopically positive for
tumor. However, it should be pointed out that since as
few as 100 tumor cells can be fatal, it is more than likely
than not that a high percentage of these animals would
have died of their brain tumors if they had been followed
for a longer period of time. The brains of the other ratsTable 3 Survival time of rats bearing F98 gliomas following C
(7.5 Gy × 2)
Survival
Treatment groupa N Mean ± SE M
Untreated 5 24.6 ± 1.1
X-irradiationb 4 30.0 ± 1.9
CED of carboplatin 5 46.8 ± 7.5
CED of carboplatin + X-ray 12 82.1 ± 15.5
aStereotactic intracerebral implantation of 103 F98 glioma cells was carried out on d
delivery at a flow rate of 0.33 μL/min. for 30 min on day 13th and 15th.
bAnimals received 15 Gy of 6 MV LINAC X-rays, delivered in two 7.5 Gy fractions on
cSurvival of >180 d. indicates that these animals have been cured of their tumors. Tshowed focal changes consisting of gliosis, scattered
infiltrates of lymphocytes and macrophages (Figure 2B)
compared to those of untreated rats (Figure 2A), which
had highly infiltrative tumors. At 2 weeks, the brains of 5
of 6 rats were microscopically positive for tumor. How-
ever, there was considerable variability in the anatomic
locations of these microscopic foci of tumor cells, includ-
ing subcortical, leptomeningeal, and the wall of the right
lateral ventricle suggesting that the whole cerebral hemi-
sphere was involved. At 3 weeks following treatment, the
brains of 5 of 7 rats were microscopically positive for
tumor, but only one of these animals had macroscopically
visible (1–2 mm) tumor, extending from the wall of the
lateral ventricle to the cortical surface. At 4 weeks, 2 of 8
rats presumptively had died of their tumors, based on aED of carboplatin (10 μg × 2) and 15 Gy X-irradiation
times (days)c % Increased life span
edian Range Mean Median
25 21–28 0 0
30 28–32 22 20
43 33–67 90 72
54.5 35 > 180(3) 234 118
. 0. Carboplatin (10 μg in 10 μL) was administered by convection enhanced
day 14th and 16th.
he number in parenthesis indicates the number of long-term survivors.
Table 4 Comparison of radiation dosing paradigns
Equivalent dosea Physical dose and fractionation regimena
Total dose 15 Gy (5 Gy × 3)b 15 Gy (7.5 Gy × 2) 20 Gy (5 Gy × 4)
Acute responding tissues (α/β = 10) 18.75 Gy 21.88 Gy 25 Gy
Late responding tissues (α/β = 2) 26.25 Gy 35.63 Gy 35 Gy
aUsing an α/β ratio of 10 for acute (tumor) effects and 2 for late (normal brain) effects, the doses indicated were at conventional 2 Gy fractions.
bDose regimen utilized in our previously published data [9].
Yang et al. Radiation Oncology 2014, 9:25 Page 6 of 9
http://www.ro-journal.com/content/9/1/2520% loss of body weight. The remaining 6 rats all showed
microscopic evidence of tumor, and in 3 animals the
tumors were macroscopically evident. It is noteworthy
that the microscopic tumor deposits were too small to be
detected by magnetic resonance imaging (MRI), where the
limit of resolution is >1 mm, which would have been
equivalent to 106 tumor cells. Therefore, neuropathologic
examination was a more powerful approach to detect a
much smaller tumor cell burden. In contrast to the rats
that received both carboplatin and X-irradiation, the
brains of animals that received a fractionated 20 Gy dose
of X-irradiation alone all had macroscopic tumors at theA
C
Figure 2 Neuropathologic correlates. (A) Brain of an untreated F98 gliom
tumor measured 4 mm in diameter, had a central zone of necrosis, and wa
rat that received 20 μg of carboplatin by CED, followed 24 hrs later by the
week later (25 d after tumor implantation). No tumor cells were identified i
superficial white matter shows debris, which possibly could have represent
lymphocytes and macrophages, and prominent white matter vacuolation.
(C) Brain of an F98 glioma bearing rat that received four 5 Gy fractions, adm
died on d 34. The tumor measured 5 mm with a prominent, necrotic centr
scattered dilated (ectatic) vessels and prominent areas of hemorrhage, both
bearing rat that received 20 μg of carboplatin on d 7 after implantation fol
tumor measured 3 mm with a central necrotic core. There are focal collage
hemorrhage, which most likely are radiation related changes. All sections wtime of death (3, 3, 5, and 7 mm in greatest dimension on
days 31, 34, 37, and 39, respectively).
Discussion
As previously reported by us [9], a 20 μg dose of carbo-
platin administered by CED over 30 min, or an 84 μg
dose given over 7 d by Alzet pumps, in combination
with X-irradiation, were shown to be non-neurotoxic.
Doubling the dose of carboplatin to 40 μg by CED or
168 μg by Alzet pump ifusion was associated with sig-
nificant neurotoxicity [9]. Therefore, the lower doses
were selected for the studies described in the presentB
D
a bearing rat that died on d. 26 following tumor implantation. The
s highly infiltrative of normal brain. (B) Brain of an F98 glioma bearing
first of four 5 Gy fractions of 6 MV photons, and was euthanized one
n this and two additional sections. There is a focal area of gliosis. The
ed tumor cells that had been killed as a result of treatment, scattered
Otherwise, the remainder of the brain was histologically unremarkable.
inistered on days 14, 15, 16 and 17 following tumor implantation and
al core and was infiltrative of surrounding white matter. There are
of which may be radiation related. (D) Brain of an F98 glioma
lowed by four 5 Gy fractions of 6 MV photons and died on d. 44. The
n deposits with hyalinization and multiple microscopic foci of
ere stained with H & E and photographed at a magnification of 200x.
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model [16] we observed that an X-ray dose of 22.5 Gy,
delivered to the whole brain, resulted in a 30% rate of
radiation related deaths. Therefore, we chose a max-
imum dose of 20 Gy, delivered to the tumor bearing
cerebral hemisphere, in four consecutive 5 Gy fractions.
As shown in the present study, this was well tolerated.
Based on the previous findings [9], in the present study
the dose of carboplatin was set at either 20 μg by CED
or 84 μg by Alzet pump delivery in combination with a
maximum radiation dose of 20 Gy to the tumor bearing
cerebral hemisphere. However, in order to determine if
the survival data could be further improved over that pre-
viously reported by us [9], we also initiated X-irradiation
at either 6 or 24 hrs following administration of carbopla-
tin or divided it into two 10μg doses on days 1 and 3 with
a 24 hr interval between drug administration by CED and
X-irradiation with two 7.5 Gy fractions.
Turning next to the biodistribution data, the purpose
of DMF treatment was to reduce interstitial pressure
within the tumor [12] and thereby enhance the uptake
and possibly the microdistribution of carboplatin. Al-
though the differences in mean tumor carboplatin values
for D alone and DMF-treated rats were not statistically
significant, there was a suggestion that those animals
that had received DMF had higher carboplatin values
with a narrower range compared to those that did not.
However, given the broad range, it would have required
two groups of 102 animals each to attain a level of statis-
tical significance (power = 0.8, α = 0.05) and it would
have been highly unlikely in small cohorts of animals to
demonstrate any significant differences in MSTs. There-
fore, such studies were not carried out. This is not
dissimilar from what was observed in the EORTC trial
evaluating the combination of RT and temozolomide
[17,18] where 573 patients were required to demonstrate
a small difference (2.5 months) in overall median sur-
vival time. Since the reduction in interstitial pressure is
transient [12], a single DMF treatment would not have
been useful in increasing carboplatin concentration in
animals that had received the drug by Alzet pump infu-
sions. Because of the transiency of the effect, we elected
to determine drug concentrations at a short time inter-
val following termination of CED. However, it is possible
that the differences in drug concentrations might have
increased over longer time intervals if there were differ-
ences in the drug uptake and efflux.
As indicated earlier, the purpose of the present study
was to determine if modification of the RT regimen and
the dosing paradigm of carboplatin would result in
improved survival data compared to those previously
reported [5-9]. The very clear-cut answer to this question
is that sustained delivery of carboplatin (84 μg in 168 μl)
by Alzet pumps in combination with either a total dose of20 Gy or, as previously reported [9], 15 Gy in three 5 Gy
fractions, produced the greatest increases in MSTs (107.7 d
vs. 111.8 d, respectively), with no treatment-related deaths.
However, this might have been due to the higher total dose
of the drug and its improved tumor microdistribution. In-
creasing the radiation dose to 20 Gy and administering car-
boplatin by CED resulted in an identical MST as that
previously reported by us (83.6 d vs. 83.4 d, respectively)
[9]. However, as shown in Table 4, the 20 Gy dose would
have resulted in 35 Gy to late responding tissues such as
vascular endothelium compared to 26.25 Gy with the 15
Gy dose. It is noteworthy that an additional dose of 6.25
Gy of 6 MV photons to the tumor, at conventional 2 Gy
fractions (Table 4), did not have any effect on the MST,
suggesting that major determinant of efficacy was drug
rather than radiation-related. As previously reported [16],
rats that received an X-ray dose of 22.5 Gy in three 7.5 Gy
fractions had a MST of 53.2 ± 4.6 d with significant radi-
ation-related morbidity. Modifying the carboplatin dosing
paradigm to two 10 μg doses and the RT regimen to two
7.5 Gy fractions resulted in an almost identical MST
(82.1 d vs. 83.4 d) as that previously reported [9].
Two possible ways that this combination therapy might be
improved would be to increase tumor uptake and the
microdistribution of carboplatin or to administer a neu-
tralizing agent to decrease systemic toxicity associated
with a higher dose of chemotherapy, as previously re-
ported with “RADPLAT” in the treatment of advanced
squamous carcinomas of the head and neck [19]. Al-
though DMF treatment marginally increased the tumor
drug concentration, it is unlikely that this would have
resulted in a significant increase in MST compared to
animals that did not receive DMF treatment.
The major problem, which has limited the strong
synergy of RT in combination with i.c. administration of
carboplatin [9], is the tremendous variability following
CED of the drug (Table 1). We hypothesize that those
animals that were cured of their tumors had higher
tumor concentrations and better microdistributions of
carboplatin. Although there may have been some differ-
ences in the sizes of the tumors at the time that the drug
was administered, this does not seem to be an adequate
explanation for the broad ranges in tumor carboplatin
concentrations that were observed. If this is the case for
a rat brain tumor model where each tumor has a volume
of ~25–30 mm3 in a cerebral hemisphere that weighs 600
mg [9], the problem is orders of magnitude greater in the
case of a patient with a highly infiltrative glioma in a cere-
bral hemisphere that weighs ~600 g. Although CED is
superior to direct intratumoral injection [20-24], it is still
a work in progress [20], and more likely than not it can be
significantly improved. As has been reported previously by
us [9], a 20 μg dose of carboplatin administered i.c. by
CED resulted in a tumor drug concentration of 10.4 μg/g,
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(20,000 μg) administered intravenously. The major ques-
tion that must be addressed, therefore, is, “How can
administration of a therapeutic agent to a brain tumor be
improved to achieve a higher and more homogeneous
distribution of various therapeutic agents?” Basically this
is a problem that will require diverse expertise to solve
but it is not unreasonable to expect that such improve-
ments will be made and that CED ultimately will prove to
be highly effective clinically [25,26].
Conclusions
Our results provide strong proof-of-principle that i.c. CED
of carboplatin alone or in combination with X-irradiation
can result in significant prolongations in MSTs and cures
of a brain tumor that has been incurable by all other
therapeutic strategies except for one [15]. As a first step in
clinically translating these findings a Phase I trial currently
is in progress at The Ohio State University to evaluate i.c.
CED of carboplatin (72 ml over 3 days) in patients with
recurrent high grade gliomas.
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